临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1256388-51-8

Ledipasvir (GS5885)

中文名称:雷迪帕韦
CAS号:1256388-51-8
分子式: C49H54F2N8O6 分子量: 889.00
产品形式: free base
研发状态: Completed
研发用途: Hepatitis C Chronic; Hematologic Malignancy
研究机构: Ain Shams University; Cairo University
研发日期: March 1 2019
研发阶段: Phase 1 : Phase 2
Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

CAS: 1256349-48-0

Chiauranib

CAS号:1256349-48-0
分子式: C27H21N3O3 分子量: 435.50
产品形式: Free base
研发状态: Completed
研发用途: Healthy Volunteers
研究机构: Chipscreen Biosciences Ltd.; H & J CRO International Inc.
研发日期: June 2 2022
研发阶段: Phase 1
Chiauranib (CS2164) selectively inhibits multiple kinase targets aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit , thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy.

CAS: 1254473-64-7

LY2874455

中文名称:4-[(1E)-2-[5-[(1R)-1-(3,5-二氯-4-吡啶基)乙氧基]-1H-吲唑-3-基]乙烯基]-1H-吡唑-1-乙醇
CAS号:1254473-64-7
分子式: C21H19Cl2N5O2 分子量: 444.31
产品形式: free base
研发状态: Completed
研发用途: Relapsed Adult Acute Myeloid Leukemia; Refractory Adult Acute Myeloid Leukemia
研究机构: Jacqueline Garcia MD; Eli Lilly and Company; Dana-Farber Cancer Institute
研发日期: August 10 2017
研发阶段: Phase 1
LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.

CAS: 1254053-43-4

Gilteritinib (ASP2215)

中文名称:吉瑞替尼
CAS号:1254053-43-4
分子式: C29H44N8O3 分子量: 552.71
产品形式: free base
研发状态: Recruiting
研发用途: AML Adult; Refractory AML; Relapsed Adult AML; FLT3-TKD Mutation; FLT3-ITD
研究机构: French Innovative Leukemia Organisation; Acute Leukemia French Association
研发日期: January 13 2024
研发阶段: Phase 2
Gilteritinib (ASP2215) is a small-molecule FLT3/AXL inhibitor with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. It inhibits FLT3 at an IC50 value that was approximately 800-fold more potent than the concentration required to inhibit c-KIT (230 nM).

CAS: 1254036-71-9

Nemiralisib

中文名称:奈米利塞
CAS号:1254036-71-9
分子式: C26H28N6O 分子量: 440.54
产品形式: free base
研发状态: Completed
研发用途: Pulmonary Disease Chronic Obstructive
研究机构: GlaxoSmithKline
研发日期: January 17 2018
研发阶段: Phase 1
Nemiralisib, also known as GSK-2269557, is a potent and selective PI3Kδ inhibitor(pKi = 9.9).

CAS: 1254036-66-2

GSK2292767

中文名称:REL-N-[5-[4-[5-[[(2R,6S)-2,6-二甲基-4-吗啉基]甲基]-2-恶唑基]-1H-吲唑-6-基]-2-甲氧基-3-吡啶基]甲烷磺酰胺
CAS号:1254036-66-2
分子式: C24H28N6O5S 分子量: 512.58
产品形式: free base
研发状态: Completed
研发用途: Asthma
研究机构: GlaxoSmithKline
研发日期: February 6 2017
研发阶段: Phase 1
GSK2292767 is a potent and selective PI3Kδ inhibitor.